David Andrews

Company: Imvax

Job title: Co-Founder, Chief Medical Officer

Seminars:

Development of Imvax’s IGV-001 for the Treatment of Newly Diagnosed Glioblastoma Utilizes a Personalized Tumor-Derived Immunotherapy Platform Exploiting the Full Antigenic Signature of GBM 11:00 am

IGV-001, an autologous cell Immunotherapy with antisense oligonucleotide (IMV-001) targeting IGF1R, is a biologic-device combination product developed from Imvax’s proprietary platform, GoldspireTM Imvax’s GBM program builds on published Phase 1b data to leverage this cell-based autologous immunotherapy to combat the immunosuppressive GBM TME A randomized, multicenter, double-blind, placebo-controlled, Phase 2b study assessing the safety and…Read more

day: Conference Day 2